Targeted Therapy VideoMacromedia Flash
Prognostic FactorsFact Sheet
Hormone Therapy VideoMacromedia Flash
Research Fast Facts: HER2-Positive Breast CancerFact Sheet
Hormone receptor status is a main factor in planning breast cancer treatment. Some breast cancer cells grow with the help of estrogen and/or progesterone (female hormones produced in the body). These cancer cells have special proteins inside, called hormone receptors. When hormones attach to hormone receptors, the cancer cells with these receptors grow.
A pathologist determines the hormone receptor status by testing the tumor tissue removed during a biopsy.
Most (about two out of three) breast cancers are hormone receptor-positive .
Hormone receptor-positive breast cancers can be treated with hormone therapies. These include tamoxifen and the aromatase inhibitors, anastrozole (Arimidex), letrozole (Femara) or exemestane (Aromasin).
Hormone receptor-negative breast cancers are not treated with hormone therapies because they do not have hormone receptors.
Breast cancers that are ER+ also tend to be PR+. And, cancers that are ER- tend to be PR-.
Sometimes, a breast cancer is positive for estrogen receptors, but negative for progesterone receptors. Because current hormone therapies are designed to treat ER+ cancers, these cases are treated the same as breast cancers that are positive for both hormone receptors.
Hormone therapies can stop tumor growth (in hormone receptor-positive cancers) by preventing the cancer cells from getting the estrogen they need to grow. They can do this in different ways. Some hormone therapies, like the drug tamoxifen, attach to hormone receptors inside the cancer cells and block estrogen from attaching to the receptors. Other therapies, like aromatase inhibitors, lower the level of estrogen in the body so the cancer cells cannot get the estrogen they need.
Hormone receptor status is also related to the chance of recurrence (the return of breast cancer after treatment). Hormone receptor-positive tumors have a slightly lower chance of breast cancer recurrence than hormone receptor-negative tumors in the first five years after diagnosis. However, after five years, this difference begins to decrease and over time, goes away [6,29].
Learn more about hormone therapies.
Learn about hormone receptor status information on a pathology report.
For a summary of research studies on hormone receptor status, visit the Breast Cancer Research section.
HER2/neu (human epidermal growth factor receptor 2), also called ErbB2, is a protein that appears on the surface of some breast cancer cells. This protein is an important part of the pathway for cell growth and survival.
About 15 to 20 percent of all breast cancers are HER2+ (you also may hear the term “HER2/neu over-expression”) [30-31]. HER2/neu status helps guide treatment.
HER2+ breast cancers can benefit from anti-HER2/neu drugs, such as the drug trastuzumab (Herceptin), which directly target the HER2/neu receptor . Trastuzumab and other anti-HER2/neu targeted therapies are not used for HER2- cancers.
Learn about trastuzumab in the treatment of early and locally advanced breast cancer.
Learn about trastuzumab, lapatinib and other targeted therapies in the treatment of metastatic breast cancer.
Learn about emerging targeted therapies for HER2/neu-positive metastatic breast cancer.
All tumors should be tested for HER2/neu status. The two common ways to determine HER2/neu status are:
Learn about HER2/neu status information on a pathology report.
How fast a tumor grows (known as its proliferation rate) can help show how aggressive a tumor is and how likely it is to spread to other parts of the body. Tumors with a high proliferation rate (those that are growing fast) often have a poorer prognosis than those with a low proliferation rate.
Proliferation rate is an important predictor of prognosis and whether or not a tumor will respond to chemotherapy. However, there are issues related to its measurement. So, while some health care providers may use it to help guide treatment options, others do not.
The Ki-67 test is a common way to measure proliferation rate. When cells are growing and dividing (proliferating), they make proteins called proliferation antigens. By counting the number of cells with these antigens, a pathologist can determine a tumor's proliferation rate.
The antibody to Ki-67 attaches itself to the proliferation antigen. The more cells the Ki-67 antibody attaches to on a tissue sample, the more likely the tumor cells are to grow and divide rapidly. The result of this test is reported as the percentage of Ki-67-positive cells. It shows whether a low, moderate or high proportion of cancer cells are in the process of dividing.
Learn about proliferation rate information on a pathology report.